AMAG Pharmaceuticals Appoints Nancy Griffith, PH.D., as Vice President of Scientific Communications and Medical Operations
April 16 2019 - 8:00AM
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the
appointment of Nancy Griffith, Ph.D., as vice president, scientific
communications and medical operations, reporting to Brian
Robinson, M.D., senior vice president, medical affairs. Dr.
Griffith will be responsible for the creation and implementation of
AMAG’s medical communications and publication strategies.
“As AMAG continues to invest in development-stage assets such as
AMAG-423 and ciraparantag, it is increasingly important to
effectively communicate and publish the clinical data supporting
these therapies,” said Dr. Robinson. “Dr. Griffith brings the
leadership and expertise necessary to develop robust medical
communications and publication strategies, adding value to our
strategic medical affairs objectives.”
Dr. Griffith brings more than 20 years of publications and
communications experience from both large and small pharmaceutical
and biotechnology companies to her new role. Most recently she
served as vice president, medical operations and communications at
Wave Life Sciences where she established the medical affairs
function to support pipeline growth, including the development and
execution of medical communications, medical publications, medical
information, and scientific writing for the company’s
portfolio.
Dr. Griffith earned a Doctor of Philosophy in Experimental
Psychology from Temple University as well as a Bachelor’s of
Science in Psychology from the University of Iowa.
Inducement Equity Awards In connection
with Dr. Griffith entering into employment with AMAG, the Board of
Directors of AMAG approved inducement awards to Dr. Griffith of (i)
an option to purchase 17,666 shares of common stock and (ii) 3,785
restricted stock units. The option will have an exercise price
equal to the closing price of AMAG’s common stock on the grant date
and will be exercisable in four equal annual installments beginning
on the first anniversary of the grant date. The option will have a
ten-year term and be subject to the terms and conditions of the
stock option agreement pursuant to which the option will be
granted. The restricted stock units will vest in three equal annual
installments beginning on the first anniversary of the grant date
and will be subject to the restricted stock unit agreement pursuant
to which the restricted stock units will be granted. These equity
awards will be granted without stockholder approval as inducements
material to Ms. Griffith entering into employment with AMAG in
accordance with NASDAQ Listing Rule 5635(c)(4).
About AMAG AMAG is a pharmaceutical company
focused on bringing innovative products to patients with unmet
medical needs. The company does this by leveraging its development
and commercial expertise to invest in and grow its pharmaceutical
products across a range of therapeutic areas, including women’s
health. For additional company information, please
visit www.amagpharma.com.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and other
federal securities laws. Any statements contained herein which do
not describe historical facts, including but not limited to
statements regarding Dr. Griffith’s responsibilities at AMAG
related to the company’s medical communications and publication
strategy and beliefs that Dr. Griffith’s leadership and expertise
will add value to AMAG’s strategic medical affairs objectives are
forward-looking statements which involve risks and uncertainties
that could cause actual results to differ materially from those
discussed in such forward-looking statements. Such risks and
uncertainties include, among others, those risks identified in
AMAG’s filings with the U.S. Securities and Exchange
Commission (the SEC), including its Annual Report on Form
10‐K for the year ended December 31, 2018, and subsequent
filings with the SEC, which are available at the SEC’s website
at www.sec.gov. Any such risks and uncertainties could
materially and adversely affect AMAG’s results of operations, its
profitability and its cash flows, which would, in turn, have a
significant and adverse impact on AMAG’s stock price. AMAG cautions
you not to place undue reliance on any forward‐looking statements,
which speak only as of the date they are made.
AMAG disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward‐looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG
Pharmaceuticals, Inc.
AMAG Pharmaceuticals Contacts: Investors: Linda
Lennox908-627-3424
Media: Sarah Connors 781-296-0722
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Mar 2024 to Apr 2024
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
From Apr 2023 to Apr 2024